<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">SULFAMETHOXAZOLE</span><br/>(sul-fa-meth-ox'a-zole)<br/><span class="topboxtradename">Sulfamethoxazole<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic, sulfonamide</span><br/><b>Prototype: </b>Sulfisoxazole<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Intermediate-acting sulfonamide antibiotic closely related to sulfisoxazole. Intestinal absorption and urinary excretion is
         slow, therefore, it is rarely used due to the potential of excessive blood level.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Sulfonamides exert their bacteriostatic action by interfering with folic acid synthesis required for bacterial growth.</p>
<h1><a name="uses">Uses</a></h1>
<p>Acute, recurrent, or chronic urinary tract infections, lymphogranuloma venereum, and other infections caused by susceptible
         organisms.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to sulfonamides; use in treatment of group A beta-hemolytic <i>Streptococcal</i> infections; infants 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired kidney or liver function; severe allergy; bronchial asthma; blood dyscrasias, patients with G6PD deficiency; pregnancy
         (category C).
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Mild to Moderate Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO Loading Dose</span> 2 g <span class="rdroute">PO Maintenance Dose</span> 1 g q812h<br/><span class="rdage">Child:</span> <span class="rdroute">PO Loading Dose</span> <i>&gt;2 mo,</i> 5060 mg/kg  <span class="rdroute">PO Maintenance Dose</span> 2530 mg/kg q12h (max: 75 mg/kg/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with fluid of patient's choice; tablet may be crushed.</li>
<li>Maintain sufficient fluid intake to produce urinary output of at least 1500 mL/24 h for children and between 3000 and 4000
            mL/24 h for adults. Concomitant administration of urinary alkalinizer may be prescribed to reduce possibility of crystalluria
            and stone formation.
         </li>
<li>Store 15°30° C (59°86° F) in tight, light-resistant containers. Do not freeze.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, peripheral neuritis, peripheral neuropathy, tinnitus, hearing loss, vertigo, insomnia, drowsiness, mental depression,
      acute psychosis, ataxia, convulsions, kernicterus (newborns). <span class="typehead">GI:</span> <span class="speceff-common">Nausea, vomiting, diarrhea,</span> abdominal pains, hepatitis, jaundice, pancreatitis, stomatitis. <span class="typehead">Hematologic:</span> Acute hemolytic anemia (especially in patients with G6PD deficiency), <span class="speceff-life">aplastic anemia</span>, methemoglobinemia, <span class="speceff-life">agranulocytosis</span>, thrombocytopenia, leukopenia, eosinophilia, hypoprothrombinemia. <span class="typehead">Body as a Whole:</span> Headache, <span class="speceff-common">fever,</span> chills, arthralgia, malaise, allergic myocarditis, serum sickness, <span class="speceff-life">anaphylactoid reactions</span>, lymphadenopathy, local reaction following IM injection, fixed drug eruptions, diuresis, overgrowth of nonsusceptible organisms,
      LE phenomenon. <span class="typehead">Skin:</span> Pruritus, urticaria, rash, erythema multiforme including <span class="speceff-both">Stevens-Johnson syndrome, exfoliative dermatitis,</span> alopecia, photosensitivity, vascular lesions. <span class="typehead">Urogenital:</span> <span class="speceff-common">Crystalluria,</span> hematuria, proteinuria, anuria, toxic nephrosis, reduction in sperm count. <span class="typehead">Metabolic:</span> Goiter, hypoglycemia. <span class="typehead">Special Senses:</span> Conjunctivitis, conjunctival or scleral infection, retardation of corneal healing (ophthalmic ointment). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">paba-containing local anesthetics</span> may antagonize sulfa's effects; <span class="classification">oral anticoagulants</span> potentiate hypoprothrombinemia; may potentiate <span class="classification">sulfonylurea</span>-induced hypoglycemia, may decrease concentrations of <b>cyclosporine;</b> may increase levels of <b>phenytoin.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Incompletely absorbed from GI tract. <span class="typehead">Peak:</span> 34 h. <span class="typehead">Distribution:</span> Distributed to most tissues, including CSF; crosses placenta. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 712 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Baseline and periodic urine C&amp;S to determine drug effectiveness; with long-term therapy, CBC, Hct and Hgb.</li>
<li>Monitor hydration status.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Take drug exactly as prescribed. Do not alter schedule or dose; take total amount prescribed unless physician changes the
            regimen.
         </li>
<li>Drink fluids liberally unless otherwise directed.</li>
<li>Report early signs of blood dyscrasias (sore throat, pallor, fever) promptly to the physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>